Although these results have promising potential outcomes, they need to be interpreted with caution in terms of safety because elafin is overexpressed in some neoplasms, including colorectal cancer [42], high-grade serous ovarian carcinoma, and basal-like breast cancer [43]. Here, PI3 is linked to breast carcinoma.